Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Enoxaparin

Enoxaparin

Introduction

Enoxaparin sodium, marketed under trade names such as Lovenox, is a low molecular weight heparin (LMWH) used widely in modern medicine as an anticoagulant. It plays a vital role in the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), and is also utilized in the management of acute coronary syndromes (ACS). Due to its predictable pharmacokinetic profile, ease of use, and reduced need for monitoring, enoxaparin has become a mainstay in anticoagulation therapy.

Pharmacological Profile

Mechanism of Action

Enoxaparin works by potentiating the action of antithrombin III, which inhibits clotting factors, particularly Factor Xa and, to a lesser extent, Factor IIa (thrombin). Its greater selectivity for Factor Xa over Factor IIa distinguishes it from unfractionated heparin (UFH), giving it a more predictable anticoagulant effect and improved safety profile.

Pharmacokinetics

Enoxaparin is administered subcutaneously and exhibits almost 100% bioavailability. Peak plasma concentrations occur 3-5 hours post-injection. It has a half-life of 4.5-7 hours and is primarily cleared by the kidneys. In patients with renal impairment, especially the elderly, accumulation can occur, necessitating dose adjustments.

Clinical Indications

1. Prophylaxis of Venous Thromboembolism

One of the most common uses of enoxaparin is the prophylaxis of VTE in hospitalized patients, particularly those undergoing orthopedic surgery (e.g., hip or knee replacement), abdominal surgery, or those with acute medical illnesses and limited mobility.

Dosing Guidelines:

  • General Medical Patients: 40 mg SC once daily

  • Abdominal Surgery: 40 mg SC once daily (started 2 hours pre-op)

  • Knee Replacement: 30 mg SC every 12 hours or 40 mg once daily

  • Hip Replacement: 30 mg SC every 12 hours or extended prophylaxis with 40 mg once daily for up to 35 days

2. Treatment of DVT and PE

Enoxaparin is a standard first-line agent for the treatment of DVT and PE. It is often used as a bridge to oral anticoagulants such as warfarin or until the therapeutic INR is achieved.

Therapeutic Dosing:

  • 1 mg/kg SC every 12 hours, or

  • 1.5 mg/kg SC once daily (for outpatient settings)

3. Acute Coronary Syndromes (ACS)

In patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI), enoxaparin reduces the risk of recurrent ischemic events when used in conjunction with aspirin.

Dosing for ACS:

  • 1 mg/kg SC every 12 hours in combination with antiplatelet therapy

4. ST-Elevation Myocardial Infarction (STEMI)

In younger patients with STEMI, enoxaparin is given as an initial IV bolus followed by SC injections. For patients aged 75 or older, the IV bolus is omitted.

Dosing in STEMI:

  • <75 years: 30 mg IV bolus + 1 mg/kg SC every 12 hours

  • ≥75 years: 0.75 mg/kg SC every 12 hours without IV bolus

Special Considerations

Renal Impairment

Because enoxaparin is cleared renally, patients with a creatinine clearance <30 mL/min require dosage adjustments to avoid drug accumulation and bleeding risks.

  • Prophylaxis: 30 mg SC once daily

  • Treatment: 1 mg/kg SC once daily

Obesity

Obese patients may require adjusted dosing based on actual body weight. Monitoring of anti-Xa levels is sometimes recommended, particularly for those at extremes of weight.

Pregnancy

Enoxaparin does not cross the placenta and is considered safe during pregnancy for prophylaxis and treatment of thromboembolism. It is preferred over warfarin, which is teratogenic.

Pediatrics

Limited data exist for pediatric use, but enoxaparin has been used successfully in children under specialist guidance. Pediatric dosing is weight-based, and monitoring is more commonly employed.

Monitoring and Laboratory Testing

Routine coagulation monitoring is not required for enoxaparin due to its predictable dose-response relationship. However, anti-Factor Xa levels can be monitored in:

  • Renal impairment

  • Obesity/extremes of body weight

  • Pregnant patients

  • Pediatric patients

Therapeutic range for anti-Xa activity:

  • Prophylaxis: 0.2-0.4 IU/mL

  • Treatment: 0.5-1.0 IU/mL (measured 4 hours post-dose)

Adverse Effects

1. Bleeding

The most significant risk with enoxaparin therapy is bleeding. Major bleeding events are rare but possible, especially in renal impairment or concurrent use of other anticoagulants/antiplatelets.

2. Thrombocytopenia

Heparin-induced thrombocytopenia (HIT), although less common with LMWHs compared to UFH, can still occur. Monitoring platelet counts is advised during prolonged therapy.

3. Injection Site Reactions

Patients may experience local irritation, pain, or erythema at the injection site.

4. Elevated Liver Enzymes

Transient increases in liver transaminases have been reported but are usually asymptomatic and reversible.

Drug Interactions

Enoxaparin should be used cautiously with:

  • Antiplatelet drugs (e.g., aspirin, clopidogrel)

  • NSAIDs (increase risk of GI bleeding)

  • Other anticoagulants (e.g., warfarin, DOACs)

Overdose and Reversal

In the event of an overdose or life-threatening bleeding, protamine sulfate can partially reverse enoxaparin's effects.

  • 1 mg of protamine neutralizes approximately 1 mg of enoxaparin if administered within 8 hours.

Storage and Handling

Enoxaparin should be stored at room temperature and protected from light. It is supplied in prefilled syringes for ease of administration.

Cost and Accessibility

Enoxaparin can be relatively expensive, particularly in countries without healthcare subsidies. Generic versions have improved accessibility. It's essential for healthcare providers to consider both efficacy and cost-effectiveness when prescribing.

Recent Research and Developments

Recent studies have evaluated the role of enoxaparin in:

  • COVID-19-associated coagulopathy: LMWHs like enoxaparin have demonstrated improved survival and reduced thrombotic complications.

  • Cancer-associated thrombosis: Enoxaparin remains a key option for preventing and treating clots in cancer patients.

  • Outpatient use and home injections: With increased emphasis on reducing hospital stays, self-injection protocols have become more common and effective.

Conclusion

Enoxaparin is a cornerstone anticoagulant in contemporary clinical practice. Its favorable pharmacological profile, diverse clinical applications, and relative ease of use make it invaluable in inpatient and outpatient settings alike. While it carries risks—chiefly bleeding—these can be mitigated through careful dosing, especially in renal impairment and vulnerable populations. As newer oral anticoagulants continue to evolve, enoxaparin retains its relevance, particularly in perioperative, pregnancy-related, and high-risk thrombosis scenarios. Clinicians must remain updated on its indications, administration, and monitoring to maximize patient outcomes and minimize complications.

References

  1. Lovenox (Enoxaparin Sodium) [Package Insert] - Sanofi-Aventis

  2. Kakkar AK, et al. Efficacy of Enoxaparin for Thromboprophylaxis. N Engl J Med. 1993.

  3. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention. Chest. 2012.

  4. Nutescu EA, et al. Low-Molecular-Weight Heparins in Renal Impairment. Pharmacotherapy. 2009.

  5. NIH Clinical Trials Database: Enoxaparin and COVID-19 Thrombosis Trials.

  6. American College of Chest Physicians Guidelines for Antithrombotic Therapy.